The HEBP1 Knockout A-549 Polyclonal Cells constitute a polyclonal CRISPR/Cas9-edited population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the HEBP1 gene. This knockout product provides a physiologically relevant loss-of-function platform for investigating HEBP1??s contributions to heme metabolism, mitochondrial function, and apoptosis. Unlike clonal isolates, the polyclonal format retains a spectrum of editing events across the cell population, thereby minimizing selection bias and enabling robust assessment of gene function in a heterogeneous cellular context.
The host cell line, A-549, is a widely utilized epithelial model originating from the alveolar basal epithelium of a 58-year-old Caucasian male diagnosed with lung adenocarcinoma. These cells exhibit an adherent morphology and retain key features of type II pneumocytes, including the expression of surfactant proteins and the ability to form polarized monolayers. A-549 cells harbor wild-type TP53 and KRAS mutations, making them a relevant system for studying oncogenic signaling, drug resistance mechanisms, and mitochondrial dynamics in non-small-cell lung cancer.
HEBP1 (heme-binding protein 1) is a mitochondrially localized protein that serves as a heme sensor and mediator of intrinsic apoptosis. Transcriptionally activated by TP53 in response to oxidative stress or DNA damage, HEBP1 interacts with BCL2 family proteins such as BAX to facilitate mitochondrial outer membrane permeabilization, leading to cytochrome c release and subsequent caspase-9 and -3 activation. HEBP1 also binds heme through its conserved domain, which can modulate the activity of mitochondrial respiratory chain complexes and influence oxidative phosphorylation. This dual function positions HEBP1 at the intersection of metabolic regulation and cell death signaling, where it promotes ROS generation when heme homeostasis is disrupted. Consequently, HEBP1 acts downstream of TP53 and oxidative stress signals while functioning upstream of caspase cascades and mitochondrial ROS production.
In the context of A-549 lung adenocarcinoma cells, which possess intact p53 signaling, HEBP1 disruption allows dissection of p53-mediated apoptotic pathways and their crosstalk with mitochondrial metabolism. This model is particularly valuable for elucidating how heme-binding proteins influence chemotherapeutic sensitivity, as many anticancer agents induce apoptosis through mitochondrial dysfunction and ROS accumulation. Studies using this knockout system can reveal whether HEBP1 acts as a tumor suppressor or a stress-response factor that paradoxically supports survival under metabolic stress, thereby informing therapeutic strategies that target mitochondrial vulnerabilities in lung cancer.
Researchers can employ these knockout cells in apoptosis assays (Annexin V, caspase activity), mitochondrial membrane potential measurements, ROS detection, colony formation, and drug sensitivity testing. Molecular analyses via western blotting, RT-qPCR, and RNA-seq enable profiling of HEBP1-dependent pathways. For technical support, contact Ascent Research.
